Evidence map›Paper›PMID 36329447›Full record

ArticleCancer cell international2022

DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort.

Ankita Chatterjee, Akash Bararia, Debopriyo Ganguly, Pronoy Kanti Mondal, Paromita Roy, Sudeep Banerjee, Shibajyoti Ghosh, Sumit Gulati, Supriyo Ghatak, Bitan Kumar Chattopadhay and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Ankita Chatterjee *National Institute of Biomedical Genomics, Kalyani, India.
Akash Bararia *Biological Sciences Division, Human Genetics Unit, Indian Statistical Institute, 203, B. T. Road, Kolkata, West Bengal, 700108, India.
Debopriyo GangulyNational Institute of Biomedical Genomics, Kalyani, India.
Pronoy Kanti MondalBiological Sciences Division, Human Genetics Unit, Indian Statistical Institute, 203, B. T. Road, Kolkata, West Bengal, 700108, India.
Paromita RoyDepartment of Pathology & Department of Gastrointestinal Surgery, Tata Medical Center, Rajarhat, Kolkata, India.
Sudeep BanerjeeDepartment of Pathology & Department of Gastrointestinal Surgery, Tata Medical Center, Rajarhat, Kolkata, India.
Shibajyoti GhoshDepartment of General Surgery, Medical College and Hospital, Kolkata, India.
Sumit GulatiDepartment of HPB Surgery, Apollo Multispecialty Hospital, Kolkata, India.
Supriyo GhatakDepartment of HPB Surgery, Apollo Multispecialty Hospital, Kolkata, India.
Bitan Kumar ChattopadhayDepartment of General Surgery, IPGMER & SSKM Hospital, Kolkata, India.
Priyadarshi BasuNational Institute of Biomedical Genomics, Kalyani, India.
Aniruddha ChatterjeeDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Nilabja SikdarBiological Sciences Division, Human Genetics Unit, Indian Statistical Institute, 203, B. T. Road, Kolkata, West Bengal, 700108, India. snilabja@isical.ac.in.
Indian Statistical Institute · INNational Institute of Biomedical Genomics · INTata Medical Center · INUniversity of Otago · NZInstitute of Post Graduate Medical Education and Research · INMedical College and Hospital, Kolkata · IN

Funding

Department of Biotechnology, Ministry of Science and Technology, India RLS/BT/Re-Entry/05/2012
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis.

methodsMethylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan-Meier survival analysis was done to study differential prognosis, during 2-5 years of follow-up.

resultsWe identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of "regulation of ion transport", "Interferon alpha/beta signalling", "morphogenesis and development" and "transcriptional dysregulation" pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort.

conclusionsEthnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient's survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages.

Indexed as

450K DNA methylationEpigenetically Dysregulated Signalling pathwaysNPY and FAIM2hyper-methylationPancreatic-ductal adenocarcinomaPoor survivalPrognostic epigenetic marker

Identifiers

PMID36329447
PMCPMC9635159
OpenAlexW4308045437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.